May 5 (Bloomberg) -- Vertex Pharmaceuticals Inc.’s experimental hepatitis C treatment knocks out so much of the rapidly mutating virus it lets drug-resistant strains grow instead, requiring multidrug cocktails to defeat it, a study said.
May 5 (Bloomberg) -- Vertex Pharmaceuticals Inc.’s experimental hepatitis C treatment knocks out so much of the rapidly mutating virus it lets drug-resistant strains grow instead, requiring multidrug cocktails to defeat it, a study said.
